Literature DB >> 17361230

A tumor suppressor and oncogene: the WT1 story.

L Yang1, Y Han, F Suarez Saiz, F Saurez Saiz, M D Minden.   

Abstract

The Wilms' tumor 1 (WT1) gene encodes a transcription factor important for normal cellular development and cell survival. The initial discovery of WT1 as the causative gene in an autosomal-recessive condition identified it as a tumor suppressor gene whose mutations are associated with urogenital disease and the development of kidney tumors. However, this view is not in keeping with the frequent finding of wild-type, full-length WT1 in human leukemia, breast cancer and several other cancers including the majority of Wilms' tumors. Rather, these observations suggest that in those conditions, WT1 has an oncogenic role in tumor formation. In this review, we explore the literature supporting both views of WT1 in human cancer and in particular human leukemias. To understand the mechanism by which WT1 can do this, we will also examine its functional activity as a transcription factor and the influence of protein partners on its dual behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361230     DOI: 10.1038/sj.leu.2404624

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  181 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  WT1: a weak spot in KRAS-induced transformation.

Authors:  Silvia Licciulli; Joseph L Kissil
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

3.  Opposite regulation of estrogen receptor-α and its variant ER-α36 by the Wilms' tumor suppressor WT1.

Authors:  Lianguo Kang; Lei Wang; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

Review 4.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

5.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

Review 6.  Transcriptional mechanisms regulating Ca(2+) homeostasis.

Authors:  Michael F Ritchie; Yandong Zhou; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2010-11-13       Impact factor: 6.817

Review 7.  Prostate stem cell antigen: a Jekyll and Hyde molecule?

Authors:  Norihisa Saeki; Jian Gu; Teruhiko Yoshida; Xifeng Wu
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

8.  WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.

Authors:  Caroline Masserot; Qingyuan Liu; Eric Nguyen; Charles-Henry Gattolliat; Dominique Valteau-Couanet; Jean Bénard; Catherine Huber; Evelyne Ségal-Bendirdjian
Journal:  Mol Oncol       Date:  2015-10-21       Impact factor: 6.603

9.  HuR antagonizes the effect of an intronic pyrimidine-rich sequence in regulating WT1 +/-KTS isoforms.

Authors:  Hui Li; Shuai Hou; Tian Hao; Sikandar Azam; Caigang Liu; Lei Shi; Haixin Lei
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

10.  PTCSC3 Is Involved in Papillary Thyroid Carcinoma Development by Modulating S100A4 Gene Expression.

Authors:  Jaroslaw Jendrzejewski; Andrew Thomas; Sandya Liyanarachchi; Andrew Eiterman; Jerneja Tomsic; Huiling He; Hanna S Radomska; Wei Li; Rebecca Nagy; Krzysztof Sworczak; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2015-08-14       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.